PDCD1 and melanoma: We have previously reported the utility of CTLA4 promoter methylation as a predictive biomarker for response to immunotherapy and survival in a heterogeneous cohort comprised of N = 50 melanoma patients who received anti-PD-1 and anti-CTLA-4 single-agent or combination immunotherapy [16].